“…SGLT-2 inhibitors are considered relatively safe drugs that could actually provide a reno-protective effect rather than harming the kidneys [ 37 , 43 , 49 , 53 , 54 , 57 , 59 , 61 ]. Indeed, although there are a handful of studies that refer to small decreases in the eGFR, which have been observed shortly after the addition of an SGLT-2 inhibitor in the medication of patients hospitalized for ADHF [ 45 , 49 ], the deterioration of renal function was mostly not persistent after hospital discharge [ 45 , 49 , 62 ]. A trial with a total of 23 patients reported two cases with an acute increase in serum creatinine, which was attenuated later at six weeks [ 42 ].…”